Table 1.
Patient characteristics
| Group I (n = 1273) | Group II (n = 476) | Total (group I + group II) (n = 1749) | Group III (n = 1884) | P1 | P2 | P3 | |
|---|---|---|---|---|---|---|---|
| Age, years | 37 (32–50) | 47 (36–60) | 39 (32–55) | 52 (38–67) | <0.001 | <0.001 | <0.001 |
| Male, n (%) | 357 (28.0) | 193 (40.6) | 550 (31.4) | 1036 (54.9) | <0.001 | <0.001 | <0.001 |
| ASA classification > 2, n (%) | 115 (9.0) | 61 (12.8) | 176 (10.1) | 35 (1.9) | <0.001 | <0.001 | <0.001 |
| Comorbidities, n (%) | |||||||
| Hypertension | 201 (15.8) | 140 (29.4) | 341 (19.5) | 206 (10.9) | <0.001 | <0.001 | <0.001 |
| DM | 110 (8.6) | 56 (11.8) | 166 (9.5) | 114 (6.1) | 0.006 | <0.001 | <0.001 |
| CRF | 26 (2.0) | 11 (2.3) | 37 (2.1) | 32 (1.7) | 0.482 | 0.372 | 0.359 |
| CAD | 77 (6.0) | 66 (13.9) | 143 (8.2) | 77 (4.1) | 0.012 | <0.001 | <0.001 |
| Immunosuppressive drug | 81 (6.4) | 94 (19.8) | 175 (10.0) | 3 (0.2) | <0.001 | <0.001 | <0.001 |
| COPD | 32 (2.5) | 42 (8.8) | 74 (4.2) | 37 (2.0) | 0.302 | <0.001 | <0.001 |
| Smoking | 218 (17.1) | 92 (19.3) | 310 (17.7) | 318 (16.9) | 0.864 | 0.208 | 0.506 |
| CVA | 18 (1.4) | 10 (2.1) | 28 (1.6) | 18 (1.0) | 0.235 | 0.039 | 0.082 |
| COVID (+) patients, n (%) | 43 (3.4) | 30 (6.3) | 73 (4.2) | 1884 (100) | <0.001 | <0.001 | <0.001 |
CAD, coronary arterial disease; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; CVA, cerebrovascular accident; DM, diabetes mellitus; group III, hospitalised COVID patients; group II, intervention patients; group I, surgical patients; P1, group I and group III; P2, group II and group III; P3, total (group I + group II) and group III.